These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30242099)

  • 1. Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells.
    Wang X; Hu CS; Petersen B; Qiu J; Ye F; Houldsworth J; Eng K; Huang F; Hoffman R
    Blood Adv; 2018 Sep; 2(18):2378-2388. PubMed ID: 30242099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells.
    Wang X; Haylock D; Hu CS; Kowalczyk W; Jiang T; Qiu J; Mosoyan G; He W; Marshall N; Mascarenhas J; Tarasova A; Brody J; Winkler D; Hoffman R
    Blood; 2016 Jun; 127(26):3398-409. PubMed ID: 27114459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis.
    Wang X; Ye F; Tripodi J; Hu CS; Qiu J; Najfeld V; Novak J; Li Y; Rampal R; Hoffman R
    Blood; 2014 Nov; 124(19):2987-95. PubMed ID: 25193869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.
    Wang X; Zhang W; Tripodi J; Lu M; Xu M; Najfeld V; Li Y; Hoffman R
    Blood; 2010 Dec; 116(26):5972-82. PubMed ID: 20858855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells.
    Wang X; Prakash S; Lu M; Tripodi J; Ye F; Najfeld V; Li Y; Schwartz M; Weinberg R; Roda P; Orazi A; Hoffman R
    J Clin Invest; 2012 Nov; 122(11):3888-99. PubMed ID: 23023702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
    Tefferi A; Lasho TL; Begna KH; Patnaik MM; Zblewski DL; Finke CM; Laborde RR; Wassie E; Schimek L; Hanson CA; Gangat N; Wang X; Pardanani A
    N Engl J Med; 2015 Sep; 373(10):908-19. PubMed ID: 26332545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.
    Lu M; Xia L; Li Y; Wang X; Hoffman R
    Blood; 2014 Jul; 124(5):771-9. PubMed ID: 24869939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.
    Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Camacho L; Fernández-Rodríguez MC; Pairet S; Besses C
    Leuk Res; 2016 Sep; 48():11-5. PubMed ID: 27427771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
    Mascarenhas J; Harrison CN; Kiladjian JJ; Komrokji RS; Koschmieder S; Vannucchi AM; Berry T; Redding D; Sherman L; Dougherty S; Peng L; Sun L; Huang F; Wan Y; Feller FM; Rizo A; Verstovsek S
    Future Oncol; 2022 Jul; 18(22):2393-2402. PubMed ID: 35510486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients.
    Wang X; Cho SY; Hu CS; Chen D; Roboz J; Hoffman R
    Exp Hematol; 2015 Feb; 43(2):100-9.e1. PubMed ID: 25461253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
    Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
    Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.
    Mascarenhas J; Komrokji RS; Palandri F; Martino B; Niederwieser D; Reiter A; Scott BL; Baer MR; Hoffman R; Odenike O; Vannucchi AM; Bussolari J; Zhu E; Rose E; Sherman L; Dougherty S; Sun L; Huang F; Wan Y; Feller FM; Rizo A; Kiladjian JJ
    J Clin Oncol; 2021 Sep; 39(26):2881-2892. PubMed ID: 34138638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.
    Joseph I; Tressler R; Bassett E; Harley C; Buseman CM; Pattamatta P; Wright WE; Shay JW; Go NF
    Cancer Res; 2010 Nov; 70(22):9494-504. PubMed ID: 21062983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling.
    Olschok K; Altenburg B; de Toledo MAS; Maurer A; Abels A; Beier F; Gezer D; Isfort S; Paeschke K; Brümmendorf TH; Zenke M; Chatain N; Koschmieder S
    Front Oncol; 2023; 13():1277453. PubMed ID: 37941547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
    Hu Y; Bobb D; Lu Y; He J; Dome JS
    Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study.
    Sollazzo D; Forte D; Polverelli N; Romano M; Perricone M; Rossi L; Ottaviani E; Luatti S; Martinelli G; Vianelli N; Cavo M; Palandri F; Catani L
    Oncotarget; 2016 Jul; 7(28):43974-43988. PubMed ID: 27304059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis.
    Mosoyan G; Kraus T; Ye F; Eng K; Crispino JD; Hoffman R; Iancu-Rubin C
    Leukemia; 2017 Nov; 31(11):2458-2467. PubMed ID: 28270692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.
    Marian CO; Cho SK; McEllin BM; Maher EA; Hatanpaa KJ; Madden CJ; Mickey BE; Wright WE; Shay JW; Bachoo RM
    Clin Cancer Res; 2010 Jan; 16(1):154-63. PubMed ID: 20048334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
    Koziel JE; Herbert BS
    Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelosuppression in Patients Treated with the Telomerase Inhibitor Imetelstat Is Not Mediated through Activation of Toll-Like Receptors.
    Baerlocher GM; Rusbuldt J; Bussolari J; Huang F
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.